By Michael Susin

 

Haleon PLC said Thursday that organic revenue for the third quarter rose, driven by increased pricing and higher volumes.

The consumer-healthcare business, which was spun out of GSK PLC and is partly owned by Pfizer Inc., reported a 10% rise in revenue for the quarter to 2.89 billion pounds ($3.28 billion). For the nine-month period, revenue rose 14% on year to GBP8.08 billion.

"Respiratory performance was strong given sustained incidences of Covid and cold and flu combined with successful innovation", it added.

Haleon--which houses Sensodyne toothpaste and Aquafresh mouthwash as well as over-the-counter medicines Panadol and Advil--upgraded its full-year guidance and currently expects organic revenue growth to be in the range of 8% and 8.5% compared with a previous range of between 6% and 8%.

Its margin of adjusted operating profit--which strips out exceptional and other one-off items is currently expected to be slightly above last year's margin of 22.8%, driven by positive foreign-exchange movements.

GSK owns 13.5% of Haleon, while Pfizer owns 32%.

 

Write to Michael Susin at michael.susin@wsj.com

 

(END) Dow Jones Newswires

November 10, 2022 02:39 ET (07:39 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Haleon (LSE:HLN)
過去 株価チャート
から 2 2024 まで 3 2024 Haleonのチャートをもっと見るにはこちらをクリック
Haleon (LSE:HLN)
過去 株価チャート
から 3 2023 まで 3 2024 Haleonのチャートをもっと見るにはこちらをクリック